Mohammad Saeid Rezaee-Zavareh

Dr. Mohammad Saeid Rezaee-Zavareh

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Hepatitis Monthly
Verified
Journal Article
Open access
PDF file
MBMahdi Ramezani Binabaj
Mahdi Ramezani Binabaj
MMMohsen Motalebi
Mohsen Motalebi
HKHamidreza Karimi-Sari
Hamidreza Karimi-Sari
MRMohammad Saeid Rezaee-Zavareh
Mohammad Saeid Rezaee-Zavareh
SASeyed Moayed Alavian
Seyed Moayed Alavian
Context: Insulin resistance is a hallmark of metabolic syndrome (MS). It has been proposed that both polycystic ovarian syndrome (PCOS) and nonalcoholic fatty liver disease (NAFLD) are correlated with Insulin resistance. Therefore, PCOS and NAFLD can be attributed with insulin resistance and therefore MS. The aim of this meta-analysis was to determine whether PCOS patients are at a high risk of NAFLD. Evidence Acquisition: Google scholar, Scopus, ISI Web of Science, Embase, MEDLINE, and some Iranian databases such as scientific information database (SID), IranMedex, and MagIran were searched to identify relevant studies. We included all papers regardless of their language from January 1985 to June 2013. By using data on prevalence of NAFLD in patients with and without PCOS, odds ratio (OR) with 95% confidence intervals (CIs) were calculated in each study. Chi-squared test was used to assess heterogeneity between studies. Results: We finally included seven eligible studies. According to chi-squared test, there was a significant heterogeneity (73.6%) between studies (P = 0.001). NAFLD prevalence was significantly higher in patients with PCOS compared to healthy control, with an overall OR of 3.93 (95% CI: 2.17, 7.11).There was no significant publication bias based on Begg's and Egger's tests. Conclusions: According to the results of this meta-analysis, there was a high risk of NAFLD in women with PCOS. We suggest evaluating patients with PCOS regarding NAFLD. Keywords: Polycystic Ovary Syndrome; Non-alcoholic Fatty Liver Disease; Insulin Resistance; Metabolic Syndrome; Meta-Analysis

13 October 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
AAAbdelrahman M Attia
Abdelrahman M Attia
MRMohammad Saeid Rezaee-Zavareh
Mohammad Saeid Rezaee-Zavareh
SHSoo Young Hwang
Soo Young Hwang
NKNaomy Kim
Naomy Kim
HAHasmik Adetyan
Hasmik Adetyan
JYJudong Yang
Judong Yang
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally. Most patients present with late diagnosis, leading to poor prognosis. This narrative review explores novel biomarkers for early HCC detection. We conducted a comprehensive literature review analyzing protein, circulating nucleic acid, metabolite, and quantitative proteomics-based biomarkers, evaluating the advantages and limitations of each approach. While established markers like alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin, and AFP-L3 remain relevant, promising candidates include circulating tumor DNA, microRNAs, long noncoding RNAs, extracellular vesicle, and metabolomic biomarkers. Multi-biomarker panels like the GALAD score, Oncoguard, and Helio liver test show promise for improved diagnostic accuracy. Non-invasive approaches like urine and gut microbiome analysis are also emerging possibilities. Integrating these novel biomarkers with current screening protocols holds significant potential for earlier HCC detection and improved patient outcomes. Future research should explore multi-biomarker panels, omics technologies, and artificial intelligence to further enhance early HCC diagnosis and management.

22 April 2020 in Liver International
Verified
Journal Article
Open access
PDF file
HKHamidreza Karimi-Sari
Hamidreza Karimi-Sari
MRMohammad Saeid Rezaee-Zavareh
Mohammad Saeid Rezaee-Zavareh
As Mendlowitz and colleagues mentioned in a recent commentary, the World Health Organization set a goal for the elimination of viral hepatitis until 2030. This means that the number of newly infected persons and related mortality should be decreased by 90% and 65%, respectively. The elimination programs focus on different parts such as testing, treatment, immunization against hepatitis B virus (HBV), preventing mother to child transmission, blood safety, and harm reduction. Now, COVID‐19 is spreading fast throughout the world and more than one million people have been affected by this virus so far. While all attentions are now on providing effective medicines and vaccines for COVID‐19, we should not forget other viruses and diseases.

20 April 2017 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
FDFardin Dolatimehr
Fardin Dolatimehr
HKHamidreza Karimi-Sari
Hamidreza Karimi-Sari
MRMohammad Saeid Rezaee-Zavareh
Mohammad Saeid Rezaee-Zavareh
SASeyed Moayed Alavian
Seyed Moayed Alavian
BBBita Behnava
Bita Behnava
HSHeidar Sharafi
Heidar Sharafi
Hepatitis C virus (HCV) infection is an important cause of chronic liver disease which has been affected 3% of world’s population. Some studies have

16 May 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SHSoo Young Hwang
Soo Young Hwang
MRMohammad Saeid Rezaee-Zavareh
Mohammad Saeid Rezaee-Zavareh
AAAbdelrahman M Attia
Abdelrahman M Attia
EKEmily A. Kaymen
Emily A. Kaymen
NTNguyen Tran
Nguyen Tran
JYJudong Yang
Judong Yang
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have become the first-line treatment of unresectable hepatocellular carcinoma (HCC). The prognostic value of immune-related adverse events (irAEs) in these patients remains controversial. We aimed to investigate the association between irAEs and clinical outcomes in patients with HCC treated with ICIs. METHODS: We searched the PubMed, Scopus, Web of Science, and Central Register of Controlled Trials databases for articles published from inception to June 2024, using keywords including ICI, HCC, and irAEs. Statistical analysis was performed with a random effects model. RESULTS: Of 3,028 studies, 24 (4,127 patients) met the criteria for inclusion. Atezolizumab plus bevacizumab was the most common treatment regimen (n = 10 studies). IrAEs were associated with an increased objective response rate (pooled relative ratio: 1.73; 95% confidence interval [CI]: 1.36–2.21, I 2 = 41%), a higher disease control rate (pooled relative ratio: 1.45; 95% CI: 1.21–1.74, I 2 = 74%), and longer progression-free survival (pooled hazard ratio [HR]: 0.66; 95% CI: 0.52–0.84, I 2 = 71%). There was a trend toward longer overall survival for patients with irAEs compared with those without (pooled HR: 0.84; 95% CI: 0.63–1.12, I 2 = 73%). Subgroup analysis indicated a survival benefit for patients with grade 1–2 irAEs (pooled HR: 0.50; 95% CI: 0.36–0.67, I 2 = 0%) and for those with endocrine irAEs (pooled HR: 0.63; 95% CI: 0.48–0.83, I 2 = 12%). DISCUSSION: The development of irAEs is associated with favorable clinical outcomes in HCC, including improved progression-free survival and higher objective response rate. Overall survival benefit was noted in patients with mild irAEs but not those with severe irAEs.

1 October 2017 in Chinese Journal of Traumatology
Verified
Journal Article
Open access
RRReza Rostami
Reza Rostami
PSPayman Salamati
Payman Salamati
KYKourosh Karimi Yarandi
Kourosh Karimi Yarandi
AKAlireza Khoshnevisan
Alireza Khoshnevisan
SSSoheil Saadat
Soheil Saadat
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar
There are some studies which showed neurofeedback therapy (NFT) can be effective in clients with traumatic brain injury (TBI) history. However, randomized controlled clinical trials are still needed for evaluation of this treatment as a standard option. This preliminary study was aimed to evaluate the effect of NFT on continuous attention (CA) and short-term memory (STM) of clients with moderate TBI using a randomized controlled clinical trial (RCT). In this preliminary RCT, seventeen eligible patients with moderate TBI were randomly allocated in two intervention and control groups. All the patients were evaluated for CA and STM using the visual continuous attention test and Wechsler memory scale-4th edition (WMS-IV) test, respectively, both at the time of inclusion to the project and four weeks later. The intervention group participated in 20 sessions of NFT through the first four weeks. Conversely, the control group participated in the same NF sessions from the fifth week to eighth week of the project. Eight subjects in the intervention group and five subjects in the control group completed the study. The mean and standard deviation of participants' age were (26.75 ± 15.16) years and (27.60 ± 8.17) years in experiment and control groups, respectively. All of the subjects were male. No significant improvement was observed in any variables of the visual continuous attention test and WMS-IV test between two groups (p ≥ 0.05). Based on our literature review, it seems that our study is the only study performed on the effect of NFT on TBI patients with control group. NFT has no effect on CA and STM in patients with moderate TBI. More RCTs with large sample sizes, more sessions of treatment, longer time of follow-up and different protocols are recommended.